Comparison of mutation profiles in MDS and AML: A single site experience

In this AMP 2022 session, Dr. McCready examines mutation profiles in AML and MDS from a large Southern Ontario cohort utilising two NGS panels, including OGT’s SureSeq™ Myeloid NGS panel. Dr. McCready illustrates how the SureSeq Myeloid NGS portfolio provides her lab with robust detection of somatic mutations in high GC- content genes such as CEBPA and structural variants such as IDTs in the FLT3 gene, among others.